<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275664</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0272</org_study_id>
    <secondary_id>NCI-2011-02660</secondary_id>
    <secondary_id>CDR0000692516</secondary_id>
    <secondary_id>GOG-0272</secondary_id>
    <secondary_id>GOG-0272</secondary_id>
    <secondary_id>GOG-0272</secondary_id>
    <secondary_id>U10CA101165</secondary_id>
    <nct_id>NCT01275664</nct_id>
  </id_info>
  <brief_title>Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer</brief_title>
  <official_title>Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in&#xD;
      preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or&#xD;
      stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or&#xD;
      prevent nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or&#xD;
      stage IV ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the frequency of chemotherapy-induced nausea and vomiting based on complete&#xD;
      response (no vomiting and no use of rescue therapy) during the 6 days following&#xD;
      intraperitoneal (IP) chemotherapy for the 3-day regimen of aprepitant (both injection and&#xD;
      capsules) in combination with granisetron transdermal system and dexamethasone in ovarian&#xD;
      cancer patients receiving IP cisplatin OR IP carboplatin.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate possible endpoints for the chemotherapy-induced nausea and vomiting,&#xD;
      including:&#xD;
&#xD;
        -  Functional Living Index-Emesis (FLIE) questionnaire scores&#xD;
&#xD;
        -  Mean vomiting, nausea and total FLIE scores and changes from baseline in FLIE scores&#xD;
&#xD;
        -  Percentages of patients with no impact on daily living (NIDL), i.e. &gt; 108/126 total FLIE&#xD;
           score II. To describe the timing of nausea and vomiting that may guide modifications to&#xD;
           the standard regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0&#xD;
      (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive&#xD;
      dexamethasone orally (PO) on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes&#xD;
      before IP platinum therapy), and aprepitant PO on days 2-3.&#xD;
&#xD;
      Patients complete the Functional Living Index--Emesis (FLIE) and a symptom diary at baseline&#xD;
      and on days 3 and 6.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to no patient population available&#xD;
  </why_stopped>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis)</measure>
    <time_frame>During the 6 days following chemotherapy</time_frame>
    <description>Number of participants who had complete control defined by no vomiting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vomiting, Nausea and Total FLIE Scores</measure>
    <time_frame>Baseline to day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Effects as Assessed by the NCI CTCAE v 4.0</measure>
    <time_frame>Up to day 6</time_frame>
    <description>Adverse events at least possibly related to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Standard Deviation of Vomiting, Nausea, and Total FLIE Scores</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Patients With NIDL Based on FLIE</measure>
    <time_frame>Up to day 6</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Nausea and Vomiting</condition>
  <condition>Ovarian Brenner Tumor</condition>
  <condition>Ovarian Clear Cell Cystadenocarcinoma</condition>
  <condition>Ovarian Endometrioid Adenocarcinoma</condition>
  <condition>Ovarian Mucinous Cystadenocarcinoma</condition>
  <condition>Ovarian Seromucinous Carcinoma</condition>
  <condition>Ovarian Serous Cystadenocarcinoma</condition>
  <condition>Stage II Ovarian Cancer</condition>
  <condition>Stage IIA Fallopian Tube Cancer</condition>
  <condition>Stage IIA Ovarian Cancer</condition>
  <condition>Stage IIB Fallopian Tube Cancer</condition>
  <condition>Stage IIB Ovarian Cancer</condition>
  <condition>Stage IIC Fallopian Tube Cancer</condition>
  <condition>Stage IIC Ovarian Cancer</condition>
  <condition>Stage IIIA Fallopian Tube Cancer</condition>
  <condition>Stage IIIA Ovarian Cancer</condition>
  <condition>Stage IIIA Primary Peritoneal Cancer</condition>
  <condition>Stage IIIB Fallopian Tube Cancer</condition>
  <condition>Stage IIIB Ovarian Cancer</condition>
  <condition>Stage IIIB Primary Peritoneal Cancer</condition>
  <condition>Stage IIIC Fallopian Tube Cancer</condition>
  <condition>Stage IIIC Ovarian Cancer</condition>
  <condition>Stage IIIC Primary Peritoneal Cancer</condition>
  <condition>Stage IV Fallopian Tube Cancer</condition>
  <condition>Stage IV Ovarian Cancer</condition>
  <condition>Stage IV Primary Peritoneal Cancer</condition>
  <condition>Undifferentiated Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adjuvant Therapy</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>adjunct therapy</other_name>
    <other_name>adjunctive therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Emend</other_name>
    <other_name>L-754030</other_name>
    <other_name>MK-0869</other_name>
    <other_name>ONO-7436</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IP</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IP</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron Transdermal Patch</intervention_name>
    <description>Apply one patch to upper arm</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Granisetron Transdermal System</other_name>
    <other_name>Sancuso</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Management of Therapy Complications</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal carcinoma&#xD;
&#xD;
               -  Stage II, III, or IV disease with optimal (=&lt; 1 cm residual disease) or&#xD;
                  suboptimal residual disease&#xD;
&#xD;
               -  All patients must have a procedure for determining diagnosis of epithelial&#xD;
                  ovarian, fallopian tube, primary peritoneal, with appropriate tissue for&#xD;
                  histologic evaluation&#xD;
&#xD;
               -  The minimum surgery required is an abdominal surgery providing tissue for&#xD;
                  histologic evaluation and establishing and documenting the primary site and&#xD;
                  stage, as well as a maximal effort at tumor debulking; if additional surgery was&#xD;
                  performed, it should have been in accordance with appropriate surgery for ovarian&#xD;
                  or peritoneal carcinoma described in the Gynecologic Oncology Group (GOG)&#xD;
                  Surgical Procedures Manual&#xD;
&#xD;
          -  Patients with the following histologic epithelial cell types are eligible:&#xD;
&#xD;
               -  Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma,&#xD;
                  undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial&#xD;
                  carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or&#xD;
                  adenocarcinoma not otherwise specified (N.O.S.)&#xD;
&#xD;
               -  However, the histologic features of the tumor must be compatible with a primary&#xD;
                  MÃ¼llerian epithelial adenocarcinoma; if doubt exists, it is recommended that the&#xD;
                  investigator should have the slides reviewed by an independent pathologist prior&#xD;
                  to entry&#xD;
&#xD;
               -  Patients may have co-existing endometrial cancer so long as the primary origin of&#xD;
                  invasive tumor is ovarian or peritoneal for clarification of synchronous primary&#xD;
                  endometrial cancer&#xD;
&#xD;
          -  Patients receiving the initial course of chemotherapy including&#xD;
&#xD;
               -  Paclitaxel 135 mg/M2 IV over 3 hours on day 1 and&#xD;
&#xD;
               -  Cisplatin 75 mg/M2 IP on day 2 OR&#xD;
&#xD;
               -  Paclitaxel 80 mg/m2 IV days 1, 8 and 15 and&#xD;
&#xD;
               -  Carboplatin AUC 6 IP on day 1&#xD;
&#xD;
          -  Prothrombin time (PT) such that international normalized ratio (INR) is &lt; 1.5 x ULN&#xD;
             (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of&#xD;
             therapeutic warfarin)&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) &lt; 1.5 times the upper limit of normal (heparin,&#xD;
             lovenox or alternative anticoagulants are acceptable)&#xD;
&#xD;
          -  Patients with a GOG Performance Status of 0, 1, or 2&#xD;
&#xD;
          -  Patients who are able to read, understand and write English; if FLIE which has been&#xD;
             translated into other languages, and validated, becomes available, then patients&#xD;
             speaking these languages can be enrolled if translation of the symptom diary can be&#xD;
             arranged dependent on availability of suitable translators&#xD;
&#xD;
          -  Patients who are able to complete the assessments&#xD;
&#xD;
          -  Patients who are able to comply with the anti-emetic therapy&#xD;
&#xD;
          -  Patients must have met pre-entry requirements&#xD;
&#xD;
          -  Patients must have signed an approved informed consent and authorization permitting&#xD;
             release of personal health information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are known to be hypersensitive to aprepitant, granisetron or any of the&#xD;
             components of the patch or to dexamethasone&#xD;
&#xD;
          -  Patients who have received prior radiotherapy to any portion of the abdominal cavity&#xD;
             or pelvis are excluded; prior radiation for localized cancer of the breast, head and&#xD;
             neck, or skin is permitted, provided that it was completed more than three years prior&#xD;
             to registration, and the patient remains free of recurrent or metastatic disease&#xD;
&#xD;
          -  Patients who have received prior chemotherapy for any abdominal or pelvic tumor&#xD;
             including neo-adjuvant chemotherapy for their ovarian or primary peritoneal cancer are&#xD;
             excluded; patients may have received prior adjuvant chemotherapy for localized breast&#xD;
             cancer, provided that it was completed more than three years prior to registration,&#xD;
             and that the patient remains free of recurrent or metastatic disease&#xD;
&#xD;
          -  Patients who are pregnant or nursing; to date, no fetal studies in animals or humans&#xD;
             have been performed; the possibility of harm to a fetus is likely&#xD;
&#xD;
          -  Patients with clinical symptoms or signs of gastrointestinal obstruction and/ or those&#xD;
             who require parenteral hydration and/or nutrition; patients with history or current&#xD;
             diagnosis of inflammatory bowel disease are not eligible&#xD;
&#xD;
          -  Patients with medical history or conditions not otherwise previously specified which&#xD;
             in the opinion of the investigator should exclude participation in this study;&#xD;
             examples of this would be hearing loss or neuropathy which would prevent tolerance to&#xD;
             cisplatin, and paclitaxel administration; the investigator should feel free to consult&#xD;
             the Study Chair or Study Co-Chairs for uncertainty in this regard&#xD;
&#xD;
          -  Patients who, in the opinion of the treating physician, have a medical condition, or&#xD;
             currently take medications, which are felt to contraindicate safe or effective&#xD;
             administration of the standard three drug anti-emetic regimen used in this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Plaxe</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sudarshan K Sharma MD Limted-Gynecologic Oncology</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <results_first_submitted>October 10, 2017</results_first_submitted>
  <results_first_submitted_qc>March 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2018</results_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Cystadenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Brenner Tumor</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was opened to patient entry on June 13, 2011 and was closed to accrual on December 12, 2011. The trial closed early because enrollment into this study was dependent on accruing patients simultaneously with GOG 252 (NCT00951496). When GOG 252 closed, there was no patient population to recruit from for this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Granisetron, Dexamethasone, Aprepitant)</title>
          <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.&#xD;
Adjuvant Therapy: Ancillary studies&#xD;
Aprepitant: Given IV and PO&#xD;
Carboplatin: Given IP&#xD;
Cisplatin: Given IP&#xD;
Dexamethasone: Given PO&#xD;
Granisetron Transdermal Patch: Apply one patch to upper arm&#xD;
Management of Therapy Complications: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible and treated patients</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Granisetron, Dexamethasone, Aprepitant)</title>
          <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.&#xD;
Adjuvant Therapy: Ancillary studies&#xD;
Aprepitant: Given IV and PO&#xD;
Carboplatin: Given IP&#xD;
Cisplatin: Given IP&#xD;
Dexamethasone: Given PO&#xD;
Granisetron Transdermal Patch: Apply one patch to upper arm&#xD;
Management of Therapy Complications: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis)</title>
        <description>Number of participants who had complete control defined by no vomiting</description>
        <time_frame>During the 6 days following chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Granisetron, Dexamethasone, Aprepitant)</title>
            <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.&#xD;
Adjuvant Therapy: Ancillary studies&#xD;
Aprepitant: Given IV and PO&#xD;
Carboplatin: Given IP&#xD;
Cisplatin: Given IP&#xD;
Dexamethasone: Given PO&#xD;
Granisetron Transdermal Patch: Apply one patch to upper arm&#xD;
Management of Therapy Complications: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis)</title>
          <description>Number of participants who had complete control defined by no vomiting</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vomiting, Nausea and Total FLIE Scores</title>
        <time_frame>Baseline to day 6</time_frame>
        <population>Data was not collected. Funding withdrawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Granisetron, Dexamethasone, Aprepitant)</title>
            <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.&#xD;
Adjuvant Therapy: Ancillary studies&#xD;
Aprepitant: Given IV and PO&#xD;
Carboplatin: Given IP&#xD;
Cisplatin: Given IP&#xD;
Dexamethasone: Given PO&#xD;
Granisetron Transdermal Patch: Apply one patch to upper arm&#xD;
Management of Therapy Complications: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vomiting, Nausea and Total FLIE Scores</title>
          <population>Data was not collected. Funding withdrawn.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Effects as Assessed by the NCI CTCAE v 4.0</title>
        <description>Adverse events at least possibly related to treatment</description>
        <time_frame>Up to day 6</time_frame>
        <population>All eligible and evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Granisetron, Dexamethasone, Aprepitant)</title>
            <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.&#xD;
Adjuvant Therapy: Ancillary studies&#xD;
Aprepitant: Given IV and PO&#xD;
Carboplatin: Given IP&#xD;
Cisplatin: Given IP&#xD;
Dexamethasone: Given PO&#xD;
Granisetron Transdermal Patch: Apply one patch to upper arm&#xD;
Management of Therapy Complications: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Effects as Assessed by the NCI CTCAE v 4.0</title>
          <description>Adverse events at least possibly related to treatment</description>
          <population>All eligible and evaluable subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean and Standard Deviation of Vomiting, Nausea, and Total FLIE Scores</title>
        <time_frame>Baseline</time_frame>
        <population>Data not collected. Funding withdrawn</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Granisetron, Dexamethasone, Aprepitant)</title>
            <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.&#xD;
Adjuvant Therapy: Ancillary studies&#xD;
Aprepitant: Given IV and PO&#xD;
Carboplatin: Given IP&#xD;
Cisplatin: Given IP&#xD;
Dexamethasone: Given PO&#xD;
Granisetron Transdermal Patch: Apply one patch to upper arm&#xD;
Management of Therapy Complications: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Mean and Standard Deviation of Vomiting, Nausea, and Total FLIE Scores</title>
          <population>Data not collected. Funding withdrawn</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Patients With NIDL Based on FLIE</title>
        <time_frame>Up to day 6</time_frame>
        <population>Data not collected. Funding withdrawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Granisetron, Dexamethasone, Aprepitant)</title>
            <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.&#xD;
Adjuvant Therapy: Ancillary studies&#xD;
Aprepitant: Given IV and PO&#xD;
Carboplatin: Given IP&#xD;
Cisplatin: Given IP&#xD;
Dexamethasone: Given PO&#xD;
Granisetron Transdermal Patch: Apply one patch to upper arm&#xD;
Management of Therapy Complications: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Patients With NIDL Based on FLIE</title>
          <population>Data not collected. Funding withdrawn.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed day 6 while on treatment and up to 30 days after day 6.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Granisetron, Dexamethasone, Aprepitant)</title>
          <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.&#xD;
Adjuvant Therapy: Ancillary studies&#xD;
Aprepitant: Given IV and PO&#xD;
Carboplatin: Given IP&#xD;
Cisplatin: Given IP&#xD;
Dexamethasone: Given PO&#xD;
Granisetron Transdermal Patch: Apply one patch to upper arm&#xD;
Management of Therapy Complications: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucositis Oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ggt Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>White Blood Cell Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Gedeon for Helen Huang, MS</name_or_title>
      <organization>NRG Oncology</organization>
      <phone>716-845-1169</phone>
      <email>lgedeon@gogstats.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

